31/03/2019
I-131 therapy for thyroid cancer
Thyroid cancer is the most common malignancy of endocrine system, representing 3,31% of new cases in the world and is the 11th most common cancer (GLOBOCAN 2018). The prognosis and treatment of thyroid cancer depend on the pathology and stages at the time of diagnosis. Treatment options for thyroid cancer include surgery, radioactive iodine (131-I) therapy, and molecular targeted therapies with several tyrosine kinase inhibitors (TKIs).
In order to know clearly about radioactive iodine (RAI, I-131) for thyroid cancer, Young Oncologists (YO) Group had a discussion which consisted of role, indication, contraindication, planning, evaluation of treatment response, side effects and complications.
YO Group hope that you had a good overview of I-131 therapy for thyroid cancer.
Thank all of you for having joined and discussed with us.
